Toronto Stock Exchange Welcomes Apotex

• Apotex Health Corp. officially begins trading on the Toronto Stock Exchange (TSX: APTX) on June 10, 2026, following the completion of its initial public offering.
• The IPO raised total gross proceeds of $1.3 billion, split between a primary treasury offering (~$850M to the company) and a secondary offering (~$450M to existing shareholders), at a price of $24.00 per share.
• The listing is celebrated as the largest life sciences IPO in TSX history by total proceeds, with a ceremonial market open scheduled for June 11.
• Statements from exchange and company leadership highlight the milestone for Canadian capital markets and the company’s global footprint.

• The release is a ceremonial announcement confirming the start of trading; it introduces no new financial, operational, or strategic information beyond what was already disclosed in the June 8 upsize and June 9 pricing news.
• The $1.3 billion total, the pricing, and the treasury/secondary split were all explicitly stated in the prior days’ releases. Today’s news merely reiterates those facts and adds celebratory commentary.
• Because the IPO was fully priced and underwritten, the act of listing does not by itself re-rate the business. The stock price will now be determined by market forces, but the news item itself is not a catalyst.

• Apotex Health Corp. is a Canadian‑based global health company and the largest Canadian‑founded pharmaceutical firm, headquartered in Toronto with regional offices in the U.S., Mexico, and India.
• Its portfolio spans generic pharmaceuticals, biosimilars, innovative branded medicines, and consumer health products.
• The company is positioned as a major player in affordable medicine, but no financial statements are available to assess historical financial performance.